Hexarelin

II. What is this compound?

Hexarelin began life as an upgrade attempt. Its parent compound, GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs , was the first-generation growth hormone-releasing peptide — effective but metabolically fragile. So researchers swapped a single building block, replacing the native tryptophan at position 2 with a D-2-methyl-tryptophan residue, and got what they wanted: greater metabolic stability and stronger receptor binding, yielding a half-life of approximately 55 to 71 minutes in human intravenous studies, longer than GHRP-6 itself. The finished molecule — also known as Examorelin — is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), molecular weight 887 Da, formula C47H58N12O6.

The upgrade came with an unrequested bonus. Like all growth hormone secretagogues, hexarelin activates the ghrelin receptor (GHSR-1a) on pituitary somatotrophs to trigger growth hormone release [2] PMID: 7957536 . But it also binds CD36, a class B scavenger receptor expressed on cardiomyocytes and other non-endocrine tissues [3] PMID: 10465272 . Ghrelin — the body's own GHSR-1a ligand — does not bind CD36 in these tissues. That makes hexarelin pharmacologically distinct from both the natural hormone and its synthetic cousins.

In research settings the peptide is administered via subcutaneous, intramuscular, or intravenous injection. Its short half-life means protocol design must account for rapid clearance, though neither the preclinical animal studies nor the limited human phase I data treat this as a barrier [4] PMID: 7957536 . What those two receptors actually do — separately and possibly together — is where the story gets interesting.

III. How it works

Hexarelin runs on two distinct receptor systems, and the contrast between them explains nearly everything interesting about this compound.

The first pathway is shared property among secretagogues. When hexarelin binds GHSR-1a on pituitary somatotrophs, it activates G-alpha-q/11 and G-alpha-i/o signaling proteins, which trigger phospholipase C (PLC), raise intracellular calcium, and prompt the release of stored growth hormone [PMID: 7910650, 7957536]. A dose-response study in healthy human volunteers confirmed the effect in humans: intravenous hexarelin at doses of 0.5 to 2 mcg/kg produced a significant, dose-dependent rise in circulating GH [5] PMID: 7957536 .

Then comes the pathway nobody else uses. CD36 — a scavenger receptor found on cardiomyocytes, macrophages, and vascular endothelium — binds hexarelin but not ghrelin, and that engagement activates protein kinase C (PKC) signaling and enhances L-type calcium current in heart muscle cells, producing a positive inotropic effect — increased contractile force — that operates independently of growth hormone [6] PMID: 10465272 .

This GH-independent cardioprotection is the most heavily researched branch of hexarelin's mechanism. Studies demonstrate protection of cardiomyocytes from apoptosis induced by angiotensin II, doxorubicin toxicity, and ischemia-reperfusion injury [PMC4178518], alongside reduced cardiac fibrosis through limited collagen deposition and inhibited fibroblast proliferation. In atherosclerosis models, hexarelin suppressed plaque formation and improved the HDL-to-LDL ratio [PMC4178518]. None of these cardiac effects are secondary to GH elevation — they arise from direct receptor engagement in cardiac tissue.

The open question is how the two pathways interact when both run simultaneously: synergistic, additive, or independent, depending on tissue context and dosing. Which raises the practical follow-up — what has the research actually measured so far?

• GHSR-1a (ghrelin receptor) agonism - stimulates GH release from pituitary somatotrophs via G-alpha-q/11 and G-alpha-i/o, PLC, and Ca2+ cascade
  PMID 7910650PMID 7957536
• CD36 cardiac receptor binding - unique to hexarelin, mediates cardioprotective effects independent of growth hormone
  PMID 10465272PMID PMC4178518
• Positive inotropic effect via PKC signaling and L-type Ca2+ current enhancement
  PMID 10465272
• Anti-apoptotic effects in cardiomyocytes - protects against angiotensin II, doxorubicin, and ischemia-reperfusion injury
  PMID PMC4178518
• Anti-fibrotic activity - reduces collagen deposition and inhibits cardiac fibroblast proliferation
  PMID PMC4178518
• Anti-atherosclerotic effects - suppresses plaque formation, improves HDL/LDL ratio
  PMID PMC4178518

IV. Research Findings

Start with the claim that draws most people here: muscle. In infant and adult rat models, hexarelin administration stimulated significant GH release, with downstream effects on protein synthesis and lean tissue accretion [7] PMID: 7910650 . The logic chain is familiar — growth hormone promotes nitrogen retention, raises protein synthesis rates, and drives skeletal muscle cell proliferation. The evidence, however, stops at preclinical: no controlled human trials have validated these muscle-building outcomes.

Where the research genuinely distinguishes itself is cardiovascular. Unlike other GHS compounds whose cardiac effects ride on GH elevation, hexarelin acts through direct CD36 binding [8] PMID: 10465272 . In post-myocardial infarction models, studies showed improved cardiac function — increased ejection fraction, reduced scar tissue, limited adverse remodeling [9] PMID: 10614623 — along with anti-apoptotic, anti-fibrotic, and anti-atherosclerotic properties in cardiac tissue [PMC4178518]. Because these effects are GH-independent, they persist even when the GH axis is blocked — which matters enormously for anyone studying heart protection as such, rather than a hormonal side effect.

Body composition adds a quieter signal. Growth hormone influences lipolysis — the breakdown of stored triglycerides — and elevates metabolic rate [10] PMID: 12379504 , and animal studies suggest hexarelin may promote fat oxidation, though the magnitude and consistency of this effect require further investigation. Preclinical anti-inflammatory findings round out the metabolic picture [11] PMID: 25645463 .

Sleep quality surfaces occasionally in anecdotal reports, plausibly linked to growth hormone's natural peak during deep sleep phases. No peer-reviewed studies have systematically examined hexarelin's effect on sleep architecture, so those accounts remain anecdotes. The cardiovascular file, by contrast, keeps growing — which makes the safety picture the natural next question.

• muscle-growth preclinical
  PMID 7910650
• cardiovascular-health preclinical
  PMID 10465272PMID 10614623PMID PMC4178518
• fat-loss preclinical
  PMID 12379504
• anti-inflammatory preclinical
  PMID 25645463

V. Dosage Context Explained

Dosing data for hexarelin arrives from three very different witnesses — human phase I intravenous studies, anecdotal reports of self-administered subcutaneous use, and preclinical animal research — and they don't carry equal weight.

Take the rigorous one first: the dose-response study in healthy human volunteers gave intravenous bolus doses of 0.5, 1, and 2 mcg/kg and recorded a clear, dose-dependent increase in circulating growth hormone, with the largest GH spike at 2 mcg/kg [12] PMID: 7957536 . That established activity in humans at low microgram-per-kilogram doses — and nothing more. The study did not examine repeated dosing, long-term effects, or subcutaneous administration.

The anecdotal tier describes subcutaneous doses of 200 mcg per injection, administered one to three times daily. These figures lack clinical validation and represent no established protocol. One physical constraint does hold across every context: the short half-life (~55–71 minutes) means the compound clears rapidly, a genuine consideration for dosing-frequency decisions in research design.

Animal studies have used 100 to 300 mcg/kg/day administered subcutaneously [13] PMID: 7910650 — numbers that resist direct translation, because species differ substantially in pharmacokinetics, receptor density, and metabolic rate. Protocol designers therefore face a landscape of reference points rather than guidelines, which places the emphasis squarely on what happens after administration: the reported effects, and their limits.

• Administration Routes

  subcutaneous

  Range

  200 mcg per injection, 1-3x daily

  anecdotal human use

• Administration Routes

  intravenous

  Range

  0.5, 1, 2 mcg/kg bolus

  human phase I dose-response study

  PMID 7957536
• Administration Routes

  subcutaneous

  Range

  100-300 mcg/kg/day

  animal studies

  PMID 7910650

VI. Side Effects: Research Context

Honest labeling first: hexarelin's reported side-effect profile derives from anecdotal accounts, limited human phase I data, and preclinical observations — not controlled clinical trials with systematic safety monitoring.

The most commonly reported effect is a transient increase in appetite, which is precisely what engaging the ghrelin receptor should produce — it's the same receptor the body uses for hunger signaling [14] PMID: 7957536 . Anecdotes also describe mild headache, transient flushing at the injection site, and water retention at higher doses; the last may relate to growth hormone's known effects on sodium retention and fluid balance.

Theoretical contraindications mirror any GH-stimulating compound: active malignancy, given growth hormone's role in cellular proliferation, and conditions of growth hormone excess such as acromegaly or gigantism. Then comes the consideration unique to hexarelin — CD36. While chronic engagement of this cardiac receptor appears protective in preclinical models, the long-term consequences of chronic CD36 modulation in human heart tissue remain unknown.

Beyond these points, the long-term safety profile in humans is simply undocumented. The absence of systematic data isn't evidence of safety; it's evidence of insufficient investigation — which is why treating hexarelin strictly as a research compound is an accurate description rather than boilerplate. How regulators classify it follows directly from that reality.

• transient increase in appetite (ghrelin receptor activation)
• mild headache (anecdotal)
• water retention at high doses (anecdotal)
• transient flushing post-injection (anecdotal)

VII. Frequently Asked Questions